127.72

1.90% -2.47

After Hours: 127.68 -0.04 -0.03%

Neurocrine Biosciences Inc (NBIX)

Overview News Price History Option Chain Financials Discussions Forecast Dividend History

Neurocrine Biosciences Inc stock is traded at $127.72, with a volume of 1.19M. It is down -1.90% in the last 24 hours and down -0.11% over the past month. Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.

Previous Close:

$130.19

Open:

$130

24h Volume:

1.19M

Relative Volume:

1.06

Market Cap:

$12.85B

Revenue:

$2.86B

Net Income/Loss:

$478.60M

P/E Ratio:

27.36

EPS:

4.6676

Net Cash Flow:

$748.70M

1W Performance:

-4.15%

1M Performance:

-0.11%

6M Performance:

-11.31%

1Y Performance:

+20.76%

1-Day Range:

$127.20

$130.34

1-Week Range:

$127.20

$134.11

52-Week Range:

$104.42

$160.18

Neurocrine Biosciences Inc Stock (NBIX) Company Profile

Name

Neurocrine Biosciences Inc

Sector

Healthcare (1113)

Industry

Drug Manufacturers - Specialty & Generic (83)

Phone

(858) 617-7600

Address

6027 EDGEWOOD BEND COURT, SAN DIEGO, CA

Employee

2,000

Twitter

Next Earnings Date

2026-05-05

Latest SEC Filings

NBIX's Discussions on Twitter

Compare NBIX vs TAK, ZTS, HLN, TEVA, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NBIX Neurocrine Biosciences Inc	127.72	13.09B	2.86B	478.60M	748.70M	4.6676
TAK Takeda Pharmaceutical Co Adr	16.63	52.60B	29.85B	776.90M	4.35B	0.2408
ZTS Zoetis Inc	116.83	48.81B	9.47B	2.67B	2.28B	6.0218
HLN Haleon Plc Adr	9.58	42.40B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	30.64	36.34B	17.41B	1.43B	1.00B	1.2182
UTHR United Therapeutics Corp	567.16	25.11B	3.18B	1.33B	1.04B	27.90

Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-24-26	Initiated	Wolfe Research	Outperform
Jan-08-26	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Oct-21-25	Initiated	Citigroup	Buy
Jul-21-25	Initiated	Truist	Buy
Jul-10-25	Initiated	Goldman	Buy
Apr-15-25	Upgrade	Needham	Hold → Buy
Apr-14-25	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Feb-11-25	Initiated	Deutsche Bank	Hold
Oct-10-24	Resumed	Raymond James	Outperform
Aug-29-24	Upgrade	Piper Sandler	Neutral → Overweight
Apr-24-24	Upgrade	Wells Fargo	Equal Weight → Overweight
Dec-13-23	Resumed	Citigroup	Neutral
Dec-12-23	Initiated	Deutsche Bank	Buy
Oct-24-23	Resumed	Cantor Fitzgerald	Overweight
Aug-21-23	Reiterated	Mizuho	Neutral
Jul-24-23	Upgrade	SVB Securities	Market Perform → Outperform
Jul-06-23	Upgrade	BMO Capital Markets	Underperform → Market Perform
May-04-23	Upgrade	Guggenheim	Neutral → Buy
Mar-30-23	Upgrade	Canaccord Genuity	Hold → Buy
Mar-03-23	Upgrade	Evercore ISI	In-line → Outperform
Feb-03-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Nov-14-22	Downgrade	Evercore ISI	Outperform → In-line
Oct-11-22	Initiated	UBS	Buy
Sep-26-22	Initiated	Wells Fargo	Equal Weight
Jun-06-22	Resumed	Jefferies	Buy
Mar-03-22	Downgrade	Piper Sandler	Overweight → Neutral
Feb-25-22	Upgrade	Goldman	Neutral → Buy
Jan-18-22	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Nov-19-21	Initiated	BMO Capital Markets	Underperform
Nov-17-21	Upgrade	JP Morgan	Neutral → Overweight
Oct-14-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Sep-23-21	Resumed	Needham	Hold
Aug-06-21	Downgrade	Canaccord Genuity	Buy → Hold
May-18-21	Resumed	Goldman	Neutral
May-06-21	Upgrade	Barclays	Equal Weight → Overweight
Feb-02-21	Initiated	Raymond James	Outperform
Sep-30-20	Initiated	The Benchmark Company	Hold
Aug-04-20	Downgrade	JP Morgan	Overweight → Neutral
Jun-29-20	Downgrade	Goldman	Buy → Neutral
Jun-09-20	Initiated	Wedbush	Outperform
Mar-06-20	Initiated	Citigroup	Buy
Feb-27-20	Initiated	Barclays	Equal Weight
Feb-24-20	Initiated	William Blair	Outperform
Feb-06-20	Initiated	Mizuho	Neutral
Feb-05-20	Reiterated	H.C. Wainwright	Buy
Dec-13-19	Downgrade	Credit Suisse	Outperform → Neutral
Aug-07-19	Initiated	RBC Capital Mkts	Outperform
Jul-16-19	Initiated	Oppenheimer	Outperform
Jun-05-19	Initiated	Guggenheim	Neutral
May-21-19	Initiated	Credit Suisse	Outperform
Apr-22-19	Upgrade	JP Morgan	Neutral → Overweight
Apr-12-19	Initiated	Evercore ISI	Outperform
Feb-06-19	Reiterated	BofA/Merrill	Buy
Jan-23-19	Downgrade	JP Morgan	Overweight → Neutral
Dec-13-18	Initiated	Goldman	Buy
Nov-21-18	Initiated	Canaccord Genuity	Buy

View All

Neurocrine Biosciences Inc Stock (NBIX) Latest News

Apr 23, 2026

Morgan Stanley Maintains Neurocrine Biosciences (NBIX) Overweight Recommendation - MSN

Apr 23, 2026

Neurocrine to buy Soleno Therapeutics for $2.9 billion - MSN

Apr 23, 2026

Deutetrabenazine Market to Witness Massive Growth by 2033 |Teva - openPR.com

Apr 23, 2026

Neurocrine reports sustained glucocorticoid reductions in CAH study By Investing.com - Investing.com India

Apr 23, 2026

Neurocrine-Soleno deal garners Wall Street praise — analyst applauds business development acumen - MSN

Apr 23, 2026

Apr 22, 2026

Neurocrine reports sustained dose reductions with CRENESSITY in CAH patients - StreetInsider

Apr 22, 2026

Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Showing Sustained Glucocorticoid Dose Reductions While Maintaining Androgen Control in Adults with Classic Congenital Adrenal Hyperplasia - ChartMill

Apr 22, 2026

NBIX Maintained by Leerink Partners -- Price Target Raised to $1 - GuruFocus

Apr 22, 2026

How Neurocrine Biosciences Inc. (NBIX) Affects Rotational Strategy Timing - Stock Traders Daily

Apr 22, 2026

Apr 21, 2026

Why this Bay Area company took a buyout offer that was nearly $2 billion less than an earlier bid - The Business Journals

Apr 21, 2026

3 Reasons Growth Investors Will Love Neurocrine (NBIX) - Yahoo Finance

Apr 21, 2026

Morgan Stanley Maintains Neurocrine Biosciences(NBIX.US) With Hold Rating, Maintains Target Price $185 - Moomoo

Apr 21, 2026

Wall Street Analysts Think Neurocrine (NBIX) Could Surge 38.79%: Read This Before Placing a Bet - Zacks Investment Research

Apr 21, 2026

NBIX Stock Price, Quote & Chart | NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) - ChartMill

Apr 21, 2026

Lobbying Update: $940,000 of NEUROCRINE BIOSCIENCES INC lobbying was just disclosed - Quiver Quantitative

Apr 21, 2026

Apr 20, 2026

Neurocrine is making a $2.9 billion bet on a new kind of drug - MSN

Apr 20, 2026

Neurocrine Biosciences (NASDAQ: SLNO) offers $53.00 per share cash to Soleno - Stock Titan

Apr 20, 2026